Ghislaine Bernard - Publications

Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.

Journal: EBioMedicine

Published: July 31, 2021

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.

Journal: Frontiers in immunology

Published: September 16, 2019

Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.

Journal: Transplantation proceedings

Published: February 11, 2019

Rituximab bioavailability in primary membranous nephropathy.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: December 13, 2018

High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: October 03, 2018

CD99 isoforms regulate CD1a expression in human monocyte-derived DCs through ATF-2/CREB-1 phosphorylation.

Journal: European journal of immunology

Published: October 23, 2015

Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.

Journal: Biochimie

Published: May 14, 2015

Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.

Journal: Journal of the American Society of Nephrology : JASN

Published: November 02, 2014

Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 27, 2014